Brief: Cartesian Therapeutics Announces Positive Topline Results From Phase 2B Trial Of Descartes-08 In Patients With Myasthenia Gravis
02/07/2024 11:50
July 2 (Reuters) - Cartesian Therapeutics Inc RNAC.O :
* CARTESIAN THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
PHASE 2B TRIAL OF DESCARTES-08 IN PATIENTS WITH MYASTHENIA
GRAVIS
* CARTESIAN THERAPEUTICS INC - TRIAL MET PRIMARY ENDPOINT
WITH
STATISTICAL SIGNIFICANCE
* CARTESIAN THERAPEUTICS INC - SAFETY PROFILE CONTINUES TO
SUPPORT
OUTPATIENT ADMINISTRATION
* CARTESIAN THERAPEUTICS INC - COMPANY EXPECTS TO HOLD
END-OF-PHASE 2 MEETING WITH FDA BY YEAR-END
* CARTESIAN THERAPEUTICS INC - ALSO ANNOUNCED POSITIVE
UPDATED
RESULTS FROM TWO PATIENTS ENROLLED IN PHASE 2A OPEN-LABEL
PORTION OF TRIAL
Source text for Eikon: ID:nGNX7CVLHL
Further company coverage: RNAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview